145 related articles for article (PubMed ID: 27823710)
1. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2016 Sep; 25():16-23. PubMed ID: 27823710
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2018 Feb; 42():7-12. PubMed ID: 29458749
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.
Bae H; Cho YW; Kim KT; Allen RP; Earley CJ
Sleep Med; 2021 Aug; 84():179-186. PubMed ID: 34157632
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.
Allen RP; Adler CH; Du W; Butcher A; Bregman DB; Earley CJ
Sleep Med; 2011 Oct; 12(9):906-13. PubMed ID: 21978726
[TBL] [Abstract][Full Text] [Related]
5. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome.
Schneider J; Krafft A; Manconi M; Hübner A; Baumann C; Werth E; Gyr T; Bassetti C
Sleep Med; 2015 Nov; 16(11):1342-1347. PubMed ID: 26498233
[TBL] [Abstract][Full Text] [Related]
6. Investigating the response to intravenous iron in restless legs syndrome: an observational study.
Hornyak M; Scholz H; Kiemen A; Kassubek J
Sleep Med; 2012 Jun; 13(6):732-5. PubMed ID: 22503006
[TBL] [Abstract][Full Text] [Related]
7. Iron for the treatment of restless legs syndrome.
Trotti LM; Becker LA
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD007834. PubMed ID: 30609006
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder.
DelRosso LM; Ferri R; Chen ML; Kapoor V; Allen RP; Mogavero MP; Picchietti DL
Sleep Med; 2021 Nov; 87():114-118. PubMed ID: 34562823
[TBL] [Abstract][Full Text] [Related]
9. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.
Trenkwalder C; Winkelmann J; Oertel W; Virgin G; Roubert B; Mezzacasa A;
Mov Disord; 2017 Oct; 32(10):1478-1482. PubMed ID: 28643901
[TBL] [Abstract][Full Text] [Related]
10. Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome.
Park HR; Choi SJ; Joo EY; Allen RP
Sleep Med; 2020 Nov; 75():81-87. PubMed ID: 32853922
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose effects on restless legs syndrome and on brain iron in patients with iron deficiency anemia.
Bae H; Cho YW; Kim KT; Li X; Earley CJ
Sleep Med; 2023 Sep; 109():128-131. PubMed ID: 37437492
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder.
DelRosso LM; Reuter-Yuill LM; Cho Y; Ferri R; Mogavero MP; Picchietti DL
Sleep Med; 2022 Dec; 100():488-493. PubMed ID: 36265207
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies.
Yang X; Yang B; Ming M; Li S; Wang F; Zhu Z; Ji C; Long J; Hu F; Xu Z; Ren H; Liu B
Sleep Med; 2019 Sep; 61():110-117. PubMed ID: 31395522
[TBL] [Abstract][Full Text] [Related]
14. Iron supplementation for restless legs syndrome - A systematic review and meta-analysis.
Avni T; Reich S; Lev N; Gafter-Gvili A
Eur J Intern Med; 2019 May; 63():34-41. PubMed ID: 30798983
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy and Safety of Intravenous Ferric Carboxymaltose for Treatment of Restless Legs Syndrome: A Multicenter, Randomized, Placebo-controlled Clinical Trial.
Earley CJ; García-Borreguero D; Falone M; Winkelman JW
Sleep; 2024 Apr; ():. PubMed ID: 38625730
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Intravenous Iron Sucrose in Hemodialysis Patients with Restless Legs Syndrome (RLS): A Randomized, Placebo-Controlled Study.
Deng Y; Wu J; Jia Q
Med Sci Monit; 2017 Mar; 23():1254-1260. PubMed ID: 28285317
[TBL] [Abstract][Full Text] [Related]
17. Does Repeated Dosing of Intravenous Ferric Carboxymaltose Alleviate Symptoms of Restless Legs Syndrome?
Park HR; Choi SJ; Joo EY
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329998
[TBL] [Abstract][Full Text] [Related]
18. A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia.
Short V; Allen R; Earley CJ; Bahrain H; Rineer S; Kashi K; Gerb J; Auerbach M
Am J Hematol; 2024 Jun; 99(6):1077-1083. PubMed ID: 38476079
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
20. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
